

Erick H Turner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4082007/publications.pdf>

Version: 2024-02-01

77
papers

8,127
citations

109137

35
h-index

79541

73
g-index

79
all docs

79
docs citations

79
times ranked

8675
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLoS Medicine, 2022, 19, e1003886.	3.9	31
2	An open science pathway for drug marketing authorization—Registered drug approval. PLoS Medicine, 2021, 18, e1003726.	3.9	12
3	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Library, 2021, 2021, CD011612.	1.5	20
4	Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open, 2020, 10, e035633.	0.8	8
5	Approval of esketamine for treatment-resistant depression — Author's reply. Lancet Psychiatry, the, 2020, 7, 236.	3.7	1
6	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. Systematic Reviews, 2020, 9, 77.	2.5	11
7	Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry, the, 2019, 6, 977-979.	3.7	104
8	Healthcare Options for People Experiencing Depression (HOPE*D): the development and pilot testing of an encounter-based decision aid for use in primary care. BMJ Open, 2019, 9, e025375.	0.8	13
9	Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials. Psychological Medicine, 2019, 49, 2020-2026.	2.7	25
10	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, The, 2018, 391, 1357-1366.	6.3	2,076
11	Antidepressants might work for people with major depression: where do we go from here?. Lancet Psychiatry, the, 2018, 5, 461-463.	3.7	23
12	Network meta-analysis of antidepressants — Authors' reply. Lancet, The, 2018, 392, 1012-1013.	6.3	3
13	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American) Tj ETQq1 1 0.784314 rgBT/Over	6.3	14
14	Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials. JAMA Oncology, 2018, 4, 1426.	3.4	52
15	You can now search FDA approval documents easily at fda.opentrials.net . BMJ: British Medical Journal, 2017, 356, j677.	2.4	4
16	Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature. BMJ Open, 2017, 7, e012886.	0.8	5
17	Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions. PLoS ONE, 2016, 11, e0153220.	1.1	80
18	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 2016, 6, e010919.	0.8	139

#	ARTICLE	IF	CITATIONS
19	Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. <i>European Neuropsychopharmacology</i> , 2016, 26, 1752-1759.	0.3	24
20	Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. <i>British Journal of Psychiatry</i> , 2016, 208, 515-521.	1.7	34
21	Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials. <i>PLoS ONE</i> , 2015, 10, e0137864.	1.1	153
22	Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders. <i>JAMA Psychiatry</i> , 2015, 72, 500.	6.0	92
23	From the FDA, we still hear mostly thunderous silence. <i>BMJ, The</i> , 2015, 351, h3763.	3.0	0
24	WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS. <i>Depression and Anxiety</i> , 2014, 31, 374-378.	2.0	141
25	Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. <i>Psychological Medicine</i> , 2014, 44, 685-695.	2.7	86
26	Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions" <i>CNS Drugs</i> , 2013, 27, 775-776.	2.7	0
27	Publication Bias, with a Focus on Psychiatry: Causes and Solutions. <i>CNS Drugs</i> , 2013, 27, 457-468.	2.7	52
28	How to access and process FDA drug approval packages for use in research. <i>BMJ, The</i> , 2013, 347, f5992-f5992.	3.0	38
29	Rethinking recommendations for screening for depression in primary care. <i>Cmaj</i> , 2012, 184, 413-418.	0.9	184
30	Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. <i>PLoS Medicine</i> , 2012, 9, e1001189.	3.9	88
31	Re-rethinking the article by Thombs and colleagues: Figure 1: <i>Cmaj</i> , 2012, 184, 438.2-439.	0.9	2
32	Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. <i>BMJ, The</i> , 2012, 345, e5155-e5155.	3.0	46
33	The Effect of Funding Source on Outcome Reporting Among Drug Trials. <i>Annals of Internal Medicine</i> , 2011, 154, 137.	2.0	1
34	Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1008.	3.8	121
35	Novel Treatment Strategies for Depression in Patients With Hepatitis C. <i>Psychosomatics</i> , 2010, 51, 357-358.	2.5	4
36	All the relevant data?. <i>BMJ: British Medical Journal</i> , 2010, 341, c6487-c6487.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Novel Treatment Strategies for Depression in Patients With Hepatitis C. <i>Psychosomatics</i> , 2010, 51, 357-358.	2.5	2
38	Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. <i>BMJ: British Medical Journal</i> , 2009, 339, b2981-b2981.	2.4	149
39	Ranking antidepressants. <i>Lancet, The</i> , 2009, 373, 1760.	6.3	17
40	Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. <i>New England Journal of Medicine</i> , 2008, 358, 252-260.	13.9	2,141
41	Closing a Loophole in the FDA Amendments Act. <i>Science</i> , 2008, 322, 44-46.	6.0	11
42	Efficacy of antidepressants. <i>BMJ: British Medical Journal</i> , 2008, 336, 516-517.	2.4	58
43	Posting FDA New Drug Application Reviews. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 859.	3.8	2
44	Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. , 2006, 109, 325-338.		266
45	Is It Always Unethical to Use a Placebo in a Clinical Trial?. <i>PLoS Medicine</i> , 2005, 2, e72.	3.9	28
46	Correction/Clarification about FDA Review Documents. <i>PLoS Medicine</i> , 2005, 2, e422.	3.9	4
47	5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. <i>Medical Hypotheses</i> , 2005, 65, 138-144.	0.8	38
48	A Taxpayer-Funded Clinical Trials Registry and Results Database. <i>PLoS Medicine</i> , 2004, 1, e60.	3.9	46
49	Strategies to Decrease Costs of Prescribing Selective Serotonin Reuptake Inhibitors at a VA Medical Center. <i>Psychiatric Services</i> , 2003, 54, 195-200.	1.1	17
50	Patients With Seasonal Affective Disorder Have Lower Odor Detection Thresholds Than Control Subjects. <i>Archives of General Psychiatry</i> , 2002, 59, 1119.	13.8	47
51	Double-Blind, Placebo-Controlled Study of Single-Dose Metergoline in Depressed Patients With Seasonal Affective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 216-220.	0.7	21
52	A Circadian Signal of Change of Season in Patients With Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 2001, 58, 1108.	13.8	246
53	Ultradian oscillations in cranial thermoregulation and electroencephalographic slow-wave activity during sleep are abnormal in humans with annual winter depression. <i>Brain Research</i> , 2000, 866, 152-167.	1.1	25
54	Monorhinal odor identification and depression scores in patients with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 1999, 56, 27-35.	2.0	49

#	ARTICLE	IF	CITATIONS
55	Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. <i>Psychiatry Research</i> , 1999, 86, 9-28.	1.7	31
56	Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. <i>Comprehensive Psychiatry</i> , 1999, 40, 234-237.	1.5	2
57	The Effects of Seasons and Light Therapy on G Protein Levels in Mononuclear Leukocytes of Patients With Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 1999, 56, 178.	13.8	44
58	Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. <i>Molecular Psychiatry</i> , 1998, 3, 175-177.	4.1	167
59	Validation of the hypomania interview guide-seasonal affective disorder (HIGH-SAD) version in patients with rapid cycling bipolar disorder. , 1998, 8, 166-168.		3
60	Treatment of a Rapidly Cycling Bipolar Patient by Using Extended Bed Rest and Darkness to Stabilize the Timing and Duration of Sleep. <i>Biological Psychiatry</i> , 1998, 43, 822-828.	0.7	155
61	Greater Improvement in Summer Than With Light Treatment in Winter in Patients With Seasonal Affective Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 1614-1616.	4.0	19
62	Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy. <i>Archives of General Psychiatry</i> , 1998, 55, 524.	13.8	143
63	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3203-3207.	1.8	39
64	Light visor maintenance of light box response. <i>American Journal of Psychiatry</i> , 1997, 154, 1172a-1172.	4.0	2
65	Seasonality and pituitary volume. <i>Psychiatry Research - Neuroimaging</i> , 1997, 74, 151-157.	0.9	32
66	Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder. <i>Biological Psychiatry</i> , 1997, 42, 122-131.	0.7	31
67	Agreement between face-to-face and telephone-administered mood ratings in patients with rapid cycling bipolar disorder. <i>Psychiatry Research</i> , 1997, 71, 129-132.	1.7	20
68	Diurnal Variation in the Direction of Mood Switches in Patients With Rapid-Cycling Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 79-84.	1.1	33
69	Effects of Exogenous Melatonin Administration and Withdrawal in Five Patients With Rapid-Cycling Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 383-388.	1.1	75
70	Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. <i>Biological Psychiatry</i> , 1996, 40, 731-735.	0.7	43
71	Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls. <i>Biological Psychiatry</i> , 1996, 40, 1267-1272.	0.7	79
72	Cognitive Performance in Seasonal Affective Disorder: Pattern Recognition and the Stroop Task. <i>Journal of Nervous and Mental Disease</i> , 1996, 184, 56-59.	0.5	17

#	ARTICLE	IF	CITATIONS
73	Effect of Season and Light Treatment Upon Hot Flashes in a Perimenopausal SAD Patient. <i>Chronobiology International</i> , 1995, 12, 290-297.	0.9	5
74	Bimodal patterns of human melatonin secretion consistent with a two-oscillator model of regulation. <i>Neuroscience Letters</i> , 1995, 194, 105-108.	1.0	49
75	Platelet [3H]paroxetine binding, 5-HT-stimulated Ca ²⁺ response, and 5-HT content in winter seasonal affective disorder. <i>Biological Psychiatry</i> , 1994, 36, 458-466.	0.7	35
76	A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. <i>Journal of Affective Disorders</i> , 1994, 32, 197-200.	2.0	20
77	Three-year follow-up of older schizophrenics: Extrapyrarnidal syndromes, psychiatric symptoms, and ventricular brain ratio. <i>Biological Psychiatry</i> , 1991, 30, 913-926.	0.7	36